I have a hunch that today is close to being a “local summit” for the share price. The Ratiopharm deal does nothing to remove the threat from the Copaxone patent case that, surprisingly, has been dismissed as a sideshow by almost everyone on Wall Street.
Teva is inarguably a major beneficiary of The Global Demographic Tailwind, and the stock will presumably do well in the long term. What I’m not so sure about is the stock’s performance during the next year or so.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.